Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Xeris Pharmaceuticals Inc (XERS)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Xeris Pharmaceuticals's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.890 +0.030    +1.61%
03/05 - Closed. Currency in USD ( Disclaimer )
After Hours
1.930
+0.040
+2.116%
19:27:06 - Real-time Data
  • Volume: 1,129,940
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 1.840 - 1.930
Type:  Equity
Market:  United States
Xeris Pharmaceuticals 1.890 +0.030 +1.61%

Xeris Pharmaceuticals Inc Company Profile

 
Get an in-depth profile of Xeris Pharmaceuticals Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

355

Equity Type

ORD

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Contact Information

Address 180 North LaSalle Street Suite 1600
Chicago, 60601
United States
Phone 844 445 5704
Fax -

Top Executives

Name Age Since Title
W. Kenneth Ward - - Member of Scientific Advisory Board
Morey W. Haymond - - Scientific Advisory Board Member
Paul R. Edick 65 2017 Chairman & CEO
Orville G. Kolterman 73 - Member of Scientific Advisory Board
John L. Brooks 70 - Scientific Advisory Board Member
Barbar-Jean Anne Bormann-Kennedy 63 2021 Independent Director
Marla S. Persky 66 2021 Independent Director
Dawn Halkuff 51 2021 Independent Director
Jeffrey W. Sherman 67 2021 Independent Director
John P. Schmid 59 2021 Lead Independent Director
John H. Johnson 64 2021 Independent Non-Executive Director
Garheng Kong 47 2021 Independent Non-Executive Director
Ricki Louise Fairley - 2023 Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

XERS Comments

Write your thoughts about Xeris Pharmaceuticals Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Abdallah Mana
Abdallah Mana Oct 08, 2020 14:24
Saved. See Saved Items.
This comment has already been saved in your Saved Items
price target around 11i think itll hit that by year end
Abdallah Mana
Abdallah Mana Jun 26, 2020 14:30
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Is the sudden drop really justified? thinking od buying in since its at 2.45 right now
Jeff laster
Jeff laster Jun 26, 2020 14:30
Saved. See Saved Items.
This comment has already been saved in your Saved Items
when you put out 20 million in public offering yes
Abdallah Mana
Abdallah Mana Jun 26, 2020 14:30
Saved. See Saved Items.
This comment has already been saved in your Saved Items
glad i bought at 3 bucks lol
Randy Myers
Randy Myers Apr 22, 2020 10:43
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This will be back over $10 in the coming months.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email